Search Results for: M Pharmaceutical Enters Into Exclusive
Articles
Quantum Genomics Enters Exclusive Licensing & Collaboration Agreement With Qilu Pharmaceutical October 22, 2020
Quantum Genomics recently announced it has entered into an exclusive licensing and collaboration agreement with Qilu Pharmaceutical to develop and commercialize….
TFF Pharmaceuticals Enters into Worldwide Licensing Agreement With UNION Therapeutics August 19, 2020
TFF Pharmaceuticals, Inc. recently announced it has entered into a worldwide exclusive licensing agreement with UNION therapeutics A/S (UNION) for...WPD Pharmaceuticals Partners With CNS Pharmaceuticals on Drug Development for Coronavirus & Other Antiviral Indications March 25, 2020
WPD Pharmaceuticals Inc. recently announced it has entered into a development agreement with CNS Pharmaceuticals, Inc. for the development of……
WPD Pharmaceuticals’ New Discovery for Cancer Targeting Drugs is Granted Patent January 9, 2020
WPD Pharmaceuticals recently announced Wake Forest University received a patent from the United States Patent and Trademark Office (USPTO) for...Disc Medicine Completes $50-Million Series A Financing, Enters Exclusive License Agreement With AbbVie October 29, 2019
Disc Medicine recently announced the completion of a $50-million Series A financing. The company’s novel approach focuses on targeting hepcidin,...Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-Focused Emerald Organic Products October 24, 2019
Amarantus will receive Emerald Preferred Stock to be valued at a minimum of $100 million in 2022, and up to double digit royalties (in addition to pass-through royalties and milestones) in exchange for worldwide, exclusive development and commercial rights to….
Cara Therapeutics Enters Commercial License Agreement With Enteris BioPharma August 21, 2019
Cara Therapeutics, Inc. recently announced it has entered into a non-exclusive commercial license agreement with Enteris BioPharma, Inc. for oral formulation rights to…..
CureVac Enters Into Exclusive Sponsored Research Agreement May 23, 2019
CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, recently announced it has entered into a...Eton Pharmaceuticals Enters Into License Agreement for Two Branded Hospital Product Candidates February 15, 2019
Eton Pharmaceuticals, Inc. recently announced that it has entered into an exclusive licensing and supply agreement with Sintetica SA, a...Immatics Enters Strategic Partnership With Genmab July 8, 2018
Immatics Biotechnologies GmbH recently announced it has entered into a research collaboration and license agreement with Genmab A/S to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancer indications.
Novacap to Expand its Pharmaceutical Offering in US With Major Acquisition June 21, 2018
Novacap recently announced it has signed an agreement to acquire Boston-based PCI Synthesis, a leading US pharmaceutical contract development and manufacturing organization (CDMO), further reinforcing Novacap’s capabilities and offering for the pharmaceutical industry.
Inovio Enters License & Collaboration Agreement With ApolloBio January 8, 2018
Inovio Pharmaceuticals, Inc. recently announced it entered an amended agreement providing ApolloBio Corporation with the exclusive right to develop and...Sarepta Therapeutics Signs Exclusive Global Collaboration November 6, 2017
Sarepta Therapeutics, Inc. recently announced it has signed a research collaboration agreement with Duke University, granting the company an option...Amyris Enters Second Major Product Development & Production Agreement With Royal DSM October 2, 2017
Amyris, Inc. recently announced it has entered into a product development and production agreement for Vitamin A with Koninklijke DSM...DFB Pharmaceuticals Forms NanOlogy & Soria for Clinical Development of Naked Nanoparticle Platform September 14, 2017
Demand for new cancer drugs is enormous with public and private investment skyrocketing for new technologies. Immunotherapies have captured much...ADVANCED DELIVERY DEVICES - Disruptive Delivery Technology Partnerships Are Key to Pharmaceutical Life Cycle Management January 16, 2017
Michael D. Hooven, MSME, believes in the challenge to deliver innovative therapies that address unmet patient needs while delivering profitable growth, and the industry is responding by embracing disruptive technology that can concurrently help on both fronts and also speed time to market for pharmaceutical products and services.
COMBINATION PRODUCTS - Device Development for Pharmaceutical & Biologic Combination Products October 4, 2016
Bill Welch says when developing a combination product, there are many things to be considered – relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding user needs, determining product requirements, as well as device manufacturing variation.
Portola Pharmaceuticals Enters Licensing Agreements Worth Up to $120 Million February 8, 2016
Portola Pharmaceuticals recently announced it has licensed lead development and commercial rights to its investigational agent andexanet alfa in Japan...Sucampo Enters Exclusive Option & Collaboration Agreement With Cancer Prevention Pharmaceuticals January 18, 2016
Sucampo Pharmaceuticals, Inc. recently announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo...Xenetic Biosciences Enters Into Asset Purchase Agreement November 20, 2015
Xenetic Biosciences, Inc. recently announced it has entered into an Asset Purchase Agreement with AS Kevelt and OJSC Pharmsynthez. Pursuant...
